Peyronie's Disease: Review of Nonsurgical Treatment Options

Urologic Clinics of North America

Volumn 38, Issue 2, 2011, Pages 195-205

  Larsen, Stephen M ^a   Levine, Laurence A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Intralesional injection; Nonsurgical; Oral therapy; Peyronie's disease; Traction

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; CARNITINE; COLCHICINE; COLLAGENASE; NICARDIPINE; PENTOXIFYLLINE; PLACEBO; PROSTAGLANDIN E1; STEROID; TAMOXIFEN CITRATE; VERAPAMIL;

ALOPECIA; ANGINA PECTORIS; ANOREXIA; APLASTIC ANEMIA; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONTUSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TREATMENT FAILURE; ECCHYMOSIS; EDEMA; ELECTROCONVULSIVE THERAPY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INDIGESTION; IONTOPHORESIS; LEUKOPENIA; MONOTHERAPY; MYALGIA; NAUSEA; PAIN; PANCYTOPENIA; PENIS ERECTION; PENIS PROSTHESIS; PEYRONIE DISEASE; PRIORITY JOURNAL; RETINOPATHY; REVIEW; SEIZURE; STOMACH DISEASE; SWELLING; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

4-AMINOBENZOIC ACID; CALCIUM CHANNEL BLOCKERS; CARNITINE; COLCHICINE; COLLAGENASES; COMBINED MODALITY THERAPY; ELECTROCONVULSIVE THERAPY; HUMANS; INTERFERONS; IONTOPHORESIS; MALE; PENILE INDURATION; PENTOXIFYLLINE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN; TRACTION; VITAMIN E;

EID: 79957490213     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.02.006     Document Type: Review

References (73)

1. de la Peyronie F. Sur quelques obstacles qui s'opposent a l'ejaculation naturelle de la semence. Mem Acad Royale Chir 1743, 1:337-342.
2. El-Sakka A.I., Hassoba H.M., Chui R.M., et al. An animal model of Peyronie's like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997, 158:2284-2290.
3. El-Sakka A.I., Hassoba H.M., Pillarisetty R.J., et al. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997, 158:1391-1394.
4. Mulhall J.P., Anderson M.S., Lubrano T., et al. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002, 14:397-405.
5. Nachtsheim D.A., Rearden A. Peyronie's disease is associated with an HLA class II antigen, HLA-DQ5, implying an autoimmune etiology. J Urol 1996, 156:1330-1334.
6. Schiavino D., Sasso F., Nucera E., et al. Immunologic findings in Peyronie's disease: a controlled study. Urology 1997, 50:764-768.
7. Cantini L.P., Ferrini M.G., Vernet D., et al. Profibrotic role of myostatin in Peyronie's disease. J Sex Med 2008, 5:1607-1622.
8. Ryu J.K., Piao S., Shin H.Y., et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease. J Sex Med 2009, 6:1284-1296.
9. Del Carlo M., Cole A.A., Levine L.A. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts. J Urol 2008, 179:2447-2455.
10. Deveci S., Hopps C.V., O'Brien K., et al. Defining the clinical characteristics of Peyronie's disease in young men. J Sex Med 2007, 4:485-490.
11. Furlow W.L., Swenson H.E., Lee R.E. Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy. J Urol 1975, 114(1):69-71.
12. Gelbard M.K., Dorey F., James K. The natural history of Peyronie's disease. J Urol 1990, 144:1376-1379.
13. Deveci S., Hopps C.V., O'Brien K., et al. A retrospective review of 307 men with Peyronie's disease. J Urol 2002, 168:1075-1079.
14. Akin-Olugbade Y., Mulhall J.P. The medical management of Peyronie's disease. Nat Clin Pract Urol 2007, 4(2):95-103.
15. Trost L.W., Gur S., Hellstrom W.J. Pharmacological management of Peyronie's disease. Drugs 2007, 67(4):527-545.
16. Taylor F.L., Levine L.A. Non-surgical therapy of Peyronie's disease. Asian J Androl 2008, 10(1):79-87.
17. Ralph D., Gonzalez-Cadavid N., Mirone V., et al. The management of Peyronie's disease: evidence-based 2010 guidelines. J Sex Med 2010, 7(7):2359-2374.
18. Scott W.W., Scardino P.L. A new concept in the treatment of Peyronie's disease. South Med J 1948, 41:173-177.
19. Sikka S.C., Hellstrom W.J. Role of oxidative stress and antioxidants in Peyronie's disease. Int J Impot Res 2002, 14:353-360.
20. Pryor J.P., Farell C.F. Controlled clinical trial of Vitamin E in Peyronie's disease. Prog Reprod Biol 1983, 9:41-45.
21. Safarinejad M.R., Hosseini S.Y., Kolahi A.A. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007, 178(4 Pt 1):1398-1403.
22. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345(22):1583-1592.
23. Furst D.E., Munster T. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics & drugs used in gout. Basic and clinical pharmacology 2001, Katzung Lange, New York. G. Bertram (Ed.).
24. Akkus E., Carrier S., Rehman J., et al. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994, 44:291-295.
25. Kadioglu A., Tefekli A., Koksal T., et al. Treatment of Peyronie's disease with oral colchicine: long term results and predictive parameters of successful outcome. Int J Impot Res 2000, 12:169-175.
26. Safarinejad M.R. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004, 16:238-243.
27. Zarafonetis C.J., Horrax T.M. Treatment of Peyronie's disease with potassium para-aminobenzoate (Potaba). J Urol 1959, 81:770-772.
28. Griffiths M.R., Priestley G.C. A comparison of morphoea and lichen sclerosus et atrophicus in vitro: the effects of para-aminobenzoate on skin fibroblasts. Acta Derm Venereol 1992, 72(1):15-18.
29. Weidner W., Schroeder-Printzen I., Rudnick J. Randomized prospective placebo controlled therapy of Peyronie's disease (IPP) with Potaba (aminobenzoate potassium). J Urol 1999, 6:205.
30. Weidner W., Hauck E.W., Schnitker J., et al. Potassium paraaminobenzoate (Potaba) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005, 47:530-536.
31. Ralph D.J., Brooks M.D., Bottazzo G.F., et al. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992, 70:648-651.
32. Colletta A.A., Wakefield L.M., Howell F.V., et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990, 62:405-409.
33. Teloken C., Rhoden E.L., Grazziotin T.M., et al. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999, 162:2003-2005.
34. Biagiotti G., Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001, 88:63-67.
35. Shindel A.W., Lin G., Ning H., et al. Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med 2010, 7(6):2077-2085.
36. Lin G., Shindel A.W., Banie L., et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 2010, 7(5):1787-1797.
37. Safarinejad M.R., Asgari M.A., Hosseini S.Y., et al. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int 2010, 106(2):240-248.
38. Althof S.E., Corty E.W., Levine S.B. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999, 53:793-799.
39. Gelbard M.K., Walsh R., Kaufman J.J. Collagenase for Peyronie's disease experimental studies. Urol Res 1982, 10:135-140.
40. Gelbard M.K., Linkner A., Kaufman J.J. The use of collagenase in the treatment of Peyronie's disease. J Urol 1985, 134:280-283.
41. Gelbard M.K., James K., Riach P., et al. Collagenase vs. placebo in the treatment of Peyronie's disease: a double blind study. J Urol 1993, 149:56-58.
42. Jordan G.H. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 2008, 5(1):180-187.
43. Glina S., Gelbard M.K., Akkus E., et al. The use of collagenase in the treatment of Peyronie's disease M.K. Gelbard, A. Lindner, and J.J. Kaufman. J Sex Med 2007, 4(5):1209-1213.
44. Roth M., Eickelberg O., Kohler E., et al. Ca2+ channel blockers modulate metabolism of collagens within the extra-cellular matrix. Proc Natl Acad Sci U S A 1996, 93:5478-5482.
45. Levine L.A., Merrick P.F., Lee R.C. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994, 151(6):1522-1524.
46. Levine L.A. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997, 158(4):1395-1399.
47. Levine L.A., Goldman K.E., Greenfield J.M. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002, 168(2):621-625.
48. Bennett N.E., Guhring P., Mulhall J.P. Intralesional verapamil prevents the progression of Peyronie's disease. Urology 2007, 69(6):1181-1184.
49. Mulhall J.P., Schiff J., Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006, 175(6):2115-2118.
50. Rehman J., Benet A., Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998, 51:620-626. 69:1181-4.
51. Soh J., Kawauchi A., Kanemitsu N., et al. Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. J Sex Med 2010, 7(11):3743-3749.
52. Shirazi M., Haghpanah A.R., Badiee M., et al. Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol 2009, 41(3):467-471.
53. Duncan M.R., Berman B., Nseyo U.O. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991, 25:89-94.
54. Wegner H.E., Andreson R., Knipsel H.H., et al. Treatment of Peyronie's disease with local interferon-alpha-2b. Eur Urol 1995, 28:236-240.
55. Wegner H.E., Andresen R., Knipsel H.H., et al. Local inter-feron-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 1997, 32:190-193.
56. Hellstrom W.J., Kendirci M., Matern R., et al. Single-blind, multicenter placebo-controlled parallel study to asses the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006, 176:394-398.
57. Inal T., Tokatli Z., Akand M., et al. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology 2006, 67:1038.
58. Levine L.A. Review of current nonsurgical management of Peyronie's disease. Int J Impot Res 2003, 15:S113-S120.
59. Palmieri A., Imbimbo C., Longo N., et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 2009, 56(2):363-369.
60. Hauck E.W., Altinkilic B.M., Ludwig M., et al. Extracorporeal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach. Eur Urol 2000, 38:663-670.
61. Stancik I., Schäfer R., Andrukhova O., et al. Effect of transdermal electromotive drug therapy on fibrogenic cytokine expression in Peyronie's disease. Urology 2009, 74(3):566-570.
62. Greenfield J.M., Shah S.J., Levine L.A. Verapamil versus saline in electromotive drug administration (EDMA) for Peyronie's disease: a double blind, placebo controlled trial. J Urol 2007, 177:972-975.
63. Weiss D.S., Kirsner R., Eaglestein W.H. Electrical stimulation and wound healing. Arch Dermatol 1990, 126(2):222-225.
64. Di Stasi S.M., Giannantoni A., Capelli G., et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int 2003, 91(9):825-829.
65. Alenghat F.J., Ingber D.E. Mechanotransduction: all signals point to cytoskeleton, matrix, and integrins. Sci STKE 2002, 2002(119):PE6.
66. Alman B.A., Naber S.P., Terek R.M., et al. Platelet-derived growth factor in fibrous musculoskeletal disorders: a study of pathologic tissue sections and in vitro primary cell cultures. J Orthop Res 1995, 13(1):67-77.
67. Brighton C.T., Fisher J.R., Levine S.E., et al. The biochemical pathway mediating the proliferative response of bone cells to a mechanical stimulus. J Bone Joint Surg Am 1996, 78(9):1337-1347.
68. Molea G., Schonauer F., Blasi F. Progressive skin extension: clinical and histological evaluation of a modified procedure using Kirschner wires. Br J Plast Surg 1999, 52(3):205-208.
69. Shapiro F. Bone development and its relation to fracture repair. The role of mesenchymal osteoblasts and surface osteoblasts. Eur Cell Mater 2008, 15:53-76.
70. Fong K.D., Trindade M.C., Wang Z., et al. Microarray analysis of mechanical shear effects on flexor tendon cells. Plast Reconstr Surg 2005, 116(5):1393-1404.
71. Levine L.A., Newell M.M. FastSize Medical Extender for the treatment of Peyronie's disease. Expert Rev Med Devices 2008, 5(3):305-310.
72. Gontero P., Di Marco M., Giubilei G., et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med 2009, 6(2):558-566.
73. Greenfield J.M. Penile traction therapy in Peyronie's disease. F1000 Med Rep 2009, 1(pii):37.